Cargando…

Pseudo-Kappa Light Chain Restricted Hematogones in Patients Receiving Daratumumab

Detalles Bibliográficos
Autores principales:	Tariq, Hamza, Zahra, Urooj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886273/ https://www.ncbi.nlm.nih.gov/pubmed/34792307 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0480

Ejemplares similares

Observations on hematogones with light chain restriction.
por: D'Ardia, Angela, et al.
Publicado: (2022)

Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease
por: Tavarozzi, Rita, et al.
Publicado: (2021)

Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall
por: Guillory, Tesha, et al.
Publicado: (2016)

B-cell precursors (hematogones) in CD34+ hematopoietic stem cell collections: a single-center experience
por: Matos, Daniel Mazza
Publicado: (2022)

A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio
por: Zhang, Suojian, et al.
Publicado: (2022)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
por: Liu, Shanshan, et al.
Publicado: (2023)

Increased hematogones in an infant with bicytopenia and leucocytosis:a case report
por: Agarwal, Kiran, et al.
Publicado: (2010)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
por: Crickx, Etienne, et al.
Publicado: (2021)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients
por: Lemonakis, Konstantinos, et al.
Publicado: (2022)

Hematogones: The Supreme Mimicker and a Cytomorphological Confounder in Acute Lymphoblastic Leukemia
por: Singh, Kanwaljeet, et al.
Publicado: (2022)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Randall-Type Monoclonal IgE Kappa Light-Heavy Chain Deposition Disease
por: Isnard, Pierre, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Restricted kappa chain expression in early ontogeny: biased utilization of V kappa exons and preferential V kappa-J kappa recombinations
Publicado: (1993)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Kappa light-chain amyloidosis of gastrointestinal tract
por: Hashimoto, Rintaro, et al.
Publicado: (2019)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Pseudo-osteomyelitis
por: Pereira, Treville, et al.
Publicado: (2017)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Pseudo Differentiation Syndrome
por: Khalaf, Dina, et al.
Publicado: (2011)

Pseudo-pulmonary oedema
por: Paliwal, Bharat, et al.
Publicado: (2014)

Atypical Nodular Pulmonary Kappa Light-Chain Deposition
por: Nellipudi, Jessy, et al.
Publicado: (2021)

A study of dermoscopic features of nail psoriasis: the pseudo-pseudo-fiber sign
por: Lencastre, Andre, et al.
Publicado: (2018)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
por: Mistry, Jayna J, et al.
Publicado: (2021)

Development and characterization of polyclonal antibody against human kappa light chain in rabbit
por: Esparvarinha, Mojgan, et al.
Publicado: (2019)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Inhibitory kappa B alpha expression in endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
por: Cerrano, Marco, et al.
Publicado: (2022)

Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells
por: Mistry, Jayna J., et al.
Publicado: (2020)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
por: Liberatore, Carmine, et al.
Publicado: (2023)

Pulsus alternans: Real and pseudo
por: Raut, Monish S., et al.
Publicado: (2014)

A case of “pseudo-ketoacidosis”
por: Kelwade, Jayant, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1phj2fd7g2vi29rmol2iuirdu4